ReviewActa dermato-venereologica2020
Update of the Management of Cutaneous Squamous-cell Carcinoma.
Review in Acta dermato-venereologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 75 citations in OpenAlex.
- A Treatment Decision Model for Cutaneous Squamous Cell Carcinoma Based on Bayesian Networks.Cancers · 2026Article
- Case Report: Marjolin ulcer characterized by squamous cell carcinoma arising from chronic wounds: clinical features, diagnostic and therapeutic challenges, and insights-a report of four cases.Frontiers in medicine · 2026Article
- Postoperative Margin Management After Conventional Excision of Facial Basal and Squamous Cell Carcinomas: A Histotype-Specific Framework.Journal of skin cancer · 2026Article
- Article
- Delayed regional metastasis from small face/scalp cutaneous squamous carcinoma: outcomes and predictors.Archives of dermatological research · 2025Article
- A population-based study using nomograms to predict overall and cancer-specific survival in HPV-associated CSCC.Cancer science · 2025Article
- Clinical and histopathological features of advanced cutaneous squamous cell carcinoma with varying responses to cemiplimab.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
- DEB-TACE combined with ici for advanced squamous cell carcinoma of the skin: a case report.Frontiers in oncology · 2025Article
- Unique Dermatological and Systemic Manifestations in a Classic Pediatric Case of Kindler Syndrome: A Case Report and Literature Review.Clinical medicine insights. Case reports · 2025Article
- Squamous Cell Carcinoma: A Clinical and Histopathological Review of a South African Tertiary Dermatology Unit.Journal of skin cancer · 2025Article
- Squamous Cell Carcinoma of the Nail Bed.The Permanente journal · 2024Article
- Article
- Development of diffuse cutaneous squamous cell carcinoma in situ after chemotherapy for ovarian carcinoma and remission with PD1-inhibitor.Gynecologic oncology reports · 2024Article
- Review
- Cutaneous Squamous Cell Carcinoma of the Head and Neck: Pathological Features and What They Mean for Prognosis and Treatment.Cancers · 2024Review
- Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation.Cancers · 2024Review
- Article
- Improved survival over time with immunotherapy in locally advanced and metastatic cutaneous squamous cell carcinomas.Journal of cancer research and clinical oncology · 2024Article
- A Panel of Potential Serum Markers Related to Angiogenesis, Antioxidant Defense and Hypoxia for Differentiating Cutaneous Squamous Cell Carcinomas from Actinic Keratoses.Journal of personalized medicine · 2024Article
- Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.Journal for immunotherapy of cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For all primary cutaneous squamous cell carcinomas (cSCCs), physical examination should include full skin examination, recording of tumour diameter and regional lymph-node-basin status. Surgery is the treatment of choice, with a minimal 5-mm margin. For elderly patients with well-differentiated tumours, other surgical modalities can be explored. Surgery for organ-transplant recipients should not be delayed. The issue with cSCC is identifying high-risk tumours with staging, as this may alter treatment and follow-up schedules. Adjuvant radiation therapy should be considered for incomplete resection, when re-excision is impossible or there are poor-prognosis histological findings. Recommendations are biannual dermatological surveillance for at least 2 years, but in elderly patients with small, well-differentiated tumours long-term follow-up is not always necessary. In case of positive lymph nodes, radical dissection is needed, with optional regional postoperative adjuvant radiation. Advanced cSCCs are defined as unresectable local, regional or distant disease requiring systemic treatment. Their only approved treatment is the PD-1 inhibitor, cemiplimab. Trials evaluating adjuvant or neo-adjuvant anti-PD-1 are ongoing. Platin-based chemo or anti-EGFR therapies are possible second-line treatments. For transplant patients, minimizing immunosuppression and switching to sirolimus must be considered at first appearance of cSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.